⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28455474 | 0.92 | — | — | |
| Ethylene Glycol SCHEMBL1644399 | 0.87 | — | — | |
| SCHEMBL31549506 | 0.86 | — | — | |
| SCHEMBL2305609 | 0.86 | — | — | |
| SCHEMBL5074894 | 0.86 | — | — | |
| SCHEMBL18947925 | 0.86 | PRKCA (0.30) | — | |
| SCHEMBL4538371 | 0.86 | — | — | |
| SCHEMBL243461 | 0.85 | — | — | |
| SCHEMBL43693 | 0.85 | PRKCA (0.32) | — | |
| SCHEMBL20568450 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064315-A1 | MULTIVALENT AND MULTIEPITOPIC ANTIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE | GENENTECH, INC. (US) | 2022-03-03 | — | — | US | disclosed |
| EP-3494139-B1 | MULTIVALENT AND MULTIEPITOPIC ANITIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-11046776-B2 | Multivalent and multiepitopic antibodies having agonistic activity and methods of use | GENENTECH, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210147562-A1 | ANTIGEN BINDING COMPLEX HAVING AGONISTIC ACTIVITY AND METHODS OF USE | GENENTECH, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10865248-B2 | Antigen binding complex having agonistic activity and methods of use | GENENTECH, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3494139-A1 | MULTIVALENT AND MULTIEPITOPIC ANITIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE | H. Hoffnabb-La Roche Ag (CH) | 2019-06-12 | — | — | EP | disclosed |
| US-20180057598-A1 | MULTIVALENT AND MULTIEPITOPIC ANTIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| EP-3280736-A1 | ANTIGEN BINDING COMPLEX HAVING AGONISTIC ACTIVITY AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2018-02-14 | — | — | EP | disclosed |
| WO-2018027204-A1 | MULTIVALENT AND MULTIEPITOPIC ANITIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE | GENENTECH, INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| US-20180022813-A1 | ANTIGEN BINDING COMPLEX HAVING AGONISTIC ACTIVITY AND METHODS OF USE | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20060246519-A1 | MONOMERIC STREPTAVIDIN MUTEINS | UTI LIMITED PARTNERSHIP (CA) | 2006-11-02 | — | — | US | disclosed |
| US-20060223156-A1 | Controlled dissolution crosslinked protein in crystals | ALTHEA TECHNOLOGIES, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2006084388-A1 | MONOMERIC STREPTAVIDIN MUTEINS | UTI LIMITED PARTNERSHIP (CA) | 2006-08-17 | — | — | WO | disclosed |
| US-20040258684-A1 | Comprising multiple heavy and light chain variable regions of monoclonal antibody; crosslinking cell surface molecules; cancer, inflammation, hormone disorders, blood diseases | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-12-23 | — | — | US | disclosed |
| US-20040242847-A1 | Monoclonal antibody for use as a preventive and/or remedy cancer, inflammation, hormone and blood diseases; immunotherapy | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20040091475-A1 | Degraded tpo agonist antibody | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | disclosed |
| US-20040073013-A1 | Polypeptide inducing apoptosis | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-15 | — | — | US | disclosed |
| US-20040058393-A1 | Agonist antibodies | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1327681-A1 | DEGRADED AGONIST ANTIBODY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1262548-A1 | POLYPEPTIDE INDUCING APOPTOSIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-12-04 | — | — | EP | disclosed |